Trial Profile
A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN 0701)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary) ; Methotrexate; Tacrolimus
- Indications Follicular lymphoma; Graft-versus-host disease
- Focus Therapeutic Use
- 03 Apr 2013 Planned end date changed from 1 Dec 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned end date changed from 1 Dec 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by (M.D. Anderson Cancer Center.